#4-19E. Navigating Biologics in RA-ILD: Survival Benefits of Abatacept vs. Rituximab (ArthritisRheumatol, 2026)

When managing rheumatoid arthritis-associated interstitial lung disease (RA-ILD), selecting the optimal biologic therapy remains a significant clinical challenge due to the limited direct head-to-head comparisons. This episode explores an emulated target trial utilizing the TriNetX US Collaborative Network database to evaluate the comparative effectiveness and safety of abatacept versus rituximab in RA-ILD patients. After propensity score matching of 1,615 patients in each cohort, the study revealed that abatacept is associated with a significantly lower risk of all-cause mortality and a reduced need for mechanical ventilation compared to rituximab. The core finding highlights that abatacept may confer a substantial survival advantage, positioning it as a highly viable biologic option for these complex cases. However, when critically appraising this study, listeners must remain cautious regarding residual confounding by indication; clinicians might preferentially prescribe abatacept for less aggressive RA-ILD presentations, meaning these associations cannot definitively prove causality. For practicing physicians, this study provides crucial real-world evidence that can immediately inform shared decision-making and optimize biologic treatment pathways to improve long-term patient outcomes in RA-ILD.

Citation: Po-Cheng Shih, James Cheng Chung Wei. Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.43332

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.